Compare XLO & IINN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XLO | IINN |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8M | 35.3M |
| IPO Year | 2021 | 2021 |
| Metric | XLO | IINN |
|---|---|---|
| Price | $0.64 | $0.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | $2.00 |
| AVG Volume (30 Days) | ★ 333.3K | 209.7K |
| Earning Date | 03-10-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $31,804,000.00 | $289,000.00 |
| Revenue This Year | $626.78 | N/A |
| Revenue Next Year | $79.08 | $9,715.95 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 588.40 | N/A |
| 52 Week Low | $0.59 | $0.40 |
| 52 Week High | $1.70 | $1.65 |
| Indicator | XLO | IINN |
|---|---|---|
| Relative Strength Index (RSI) | 40.75 | 36.71 |
| Support Level | $0.63 | $0.75 |
| Resistance Level | $0.63 | $0.97 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 32.53 | 20.98 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.